Literature DB >> 9280214

Nitric oxide synthase inhibitors and hypertension in children and adolescents.

C D Goonasekera1, D D Rees, P Woolard, A Frend, V Shah, M J Dillon.   

Abstract

OBJECTIVE: To establish the role played by the circulating nitric oxide synthase inhibitors N(G)-monomethyl-L-arginine (L-NMMA), asymmetrical dimethyl arginine (ADMA) and symmetric dimethyl arginine (SDMA) and its association with hypertension of children and adolescents.
DESIGN: We measured plasma concentrations of L-NMMA, ADMA and SDMA in 38 hypertensives (median age 7.7 years) and in nine healthy normotensive controls (median age 8.2 years) using high-performance liquid chromatography. In addition, their plasma renin activity was determined. The subjects' glomerular filtration rates were calculated from plasma creatinine and height measurements. To determine the vasoactive potency of the arginine analogues, concentration-response curves were plotted for the responses in isolated endothelium-intact and endothelium-denuded mouse aortic rings that had been pre-contracted by administration of a threshold concentration of phenylephrine.
RESULTS: Plasma ADMA and SDMA concentrations in members of the hypertensive group [0.23 +/- 0.03 and 1.37 +/- 0.06 micromol/l, respectively (means +/- SEM)] were significantly higher than those in members of the control group (ADMA 0.10 +/- 0.01 micromol/l and SDMA 1.18 +/- 0.06 micromol/l). Plasma concentrations of L-NMMA were similar in members of the hypertensive (0.21 +/- 0.01 micromol/l) and control (0.18 +/- 0.02 micromol/l) groups. The glomerular filtration rate of the hypertensive group was below normal [70.4 +/- 5.4 ml/min per 1.73 m2 (mean +/- SEM)] and was significantly associated with elevated plasma concentrations of ADMA (r = -0.77, P < 0.001), SDMA (r = -0.38, P = 0.02) and L-NMMA (r = 0.35, P = 0.03). Higher plasma ADMA concentrations were associated with a lower plasma renin activity (r = -0.36, P = 0.04). The vasoactive potencies of ADMA (concentration for half-maximal effect with the endothelium intact 25.4 +/- 7.1 micromol/l) and L-NMMA (concentration for half-maximal effect with the endothelium intact 8.2 +/- 2.9 micromol/l) was significantly (P < 0.05) greater than that of SDMA. Both ADMA and L-NMMA (at 3 micromol/l concentrations) initiated a significant vasocontractile response from baseline (P = 0.03 and P < 0.001, respectively). These effects were absent after the endothelium had been removed. SDMA had no effect.
CONCLUSIONS: Plasma ADMA and SDMA levels are increased in hypertensive children. By inference from in-vitro data, ADMA appears to attain sufficient concentrations to produce a significant change in vascular tone and hence might play a role in the pathophysiology of childhood hypertension.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9280214     DOI: 10.1097/00004872-199715080-00015

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  29 in total

1.  Nitric oxide synthase, ADMA, SDMA, and nitric oxide activity in the paraventricular nucleus throughout the etiology of renal wrap hypertension.

Authors:  Carrie A Northcott; Scott Billecke; Teresa Craig; Carmen Hinojosa-Laborde; Kaushik P Patel; Alex F Chen; Louis G D'Alecy; Joseph R Haywood
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-03-23       Impact factor: 4.733

Review 2.  The role of asymmetric and symmetric dimethylarginines in renal disease.

Authors:  Edzard Schwedhelm; Rainer H Böger
Journal:  Nat Rev Nephrol       Date:  2011-03-29       Impact factor: 28.314

3.  Changes in ghrelin and asymmetrical dimethylarginine in obese Mexican adolescents after six-month lifestyle intervention.

Authors:  Fengyang Huang; Blanca Estela del-Río-Navarro; José Alfredo Pérez Ontiveros; Eliseo Ruiz-Bedolla; Efraín Navarro-Olivos; Santiago Villafaña; Guadalupe Bravo; Enrique Hong
Journal:  Endocrine       Date:  2012-09-29       Impact factor: 3.633

4.  Dimethylarginines in chronic renal failure.

Authors:  N Wahbi; R N Dalton; C Turner; M Denton; I Abbs; R Swaminathan
Journal:  J Clin Pathol       Date:  2001-06       Impact factor: 3.411

Review 5.  Nitric oxide insufficiency and atherothrombosis.

Authors:  Barbara Voetsch; Richard C Jin; Joseph Loscalzo
Journal:  Histochem Cell Biol       Date:  2004-08-26       Impact factor: 4.304

Review 6.  Asymmetric dimethylarginine as a mediator of vascular dysfunction in cirrhosis.

Authors:  Paloma Lluch; Gloria Segarra; Pascual Medina
Journal:  World J Gastroenterol       Date:  2015-08-28       Impact factor: 5.742

7.  Methylated arginine derivatives in children and adolescents with chronic kidney disease.

Authors:  Ellen R Brooks; Craig B Langman; Sihe Wang; Heather E Price; Abigail L Hodges; Lara Darling; Amy Z Yang; Frederick A Smith
Journal:  Pediatr Nephrol       Date:  2008-10-02       Impact factor: 3.714

Review 8.  Cellular ADMA: regulation and action.

Authors:  Tom Teerlink; Zaiming Luo; Fredrik Palm; Christopher S Wilcox
Journal:  Pharmacol Res       Date:  2009-08-12       Impact factor: 7.658

9.  Asymmetric dimethylarginine levels in thyroid diseases.

Authors:  E Arikan; C H Karadag; S Guldiken
Journal:  J Endocrinol Invest       Date:  2007-03       Impact factor: 4.256

10.  Proteomics analysis of human skeletal muscle reveals novel abnormalities in obesity and type 2 diabetes.

Authors:  Hyonson Hwang; Benjamin P Bowen; Natalie Lefort; Charles R Flynn; Elena A De Filippis; Christine Roberts; Christopher C Smoke; Christian Meyer; Kurt Højlund; Zhengping Yi; Lawrence J Mandarino
Journal:  Diabetes       Date:  2009-10-15       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.